-
Homologous Recombination Defects Predict Olaparib Response i
2026-06-23
Borchert et al. (2019) investigated how homologous recombination repair pathway alterations, particularly 'BRCAness' phenotypes, influence sensitivity to olaparib in malignant pleural mesothelioma (MPM) cell models. Their findings identify molecular signatures that may stratify patients for PARP inhibitor therapies and provide mechanistic context for optimizing chemotherapy strategies involving pemetrexed.
-
Salvianolic Acid B in Pulmonary Fibrosis: Applied Protocols
2026-06-22
Salvianolic acid B (Dan Shen Suan B) is transforming pulmonary fibrosis research by targeting LH2-mediated collagen cross-linking with high selectivity and potency. This article delivers protocol-driven guidance, advanced troubleshooting, and a practical translation of recent breakthrough findings to empower ECM remodeling studies using research-grade Salvianolic acid B from APExBIO.
-
Sodium Oxamate for Cancer Metabolism and Neurorepair Assays
2026-06-22
Sodium Oxamate enables rigorous interrogation of glycolytic reprogramming in both cancer and neurodegenerative models, targeting LDH-A with high specificity. Recent studies reveal its unique impact on white matter injury post-hemorrhage, setting it apart as an indispensable tool for metabolic and epigenetic research.
-
Annexin V, Human Recombinant: Beyond Apoptosis Detection in
2026-06-21
Explore how Annexin V, a premier phosphatidylserine binding protein, is transforming apoptosis assay precision and uncovering new insights in cancer metabolism. This article uniquely connects metabolic rewiring in cancer with advanced cell death research for next-generation experimental design.
-
PKH26 Red Fluorescent Cell Linker Kit: Technical Lab Guidanc
2026-06-20
The PKH26 Red Fluorescent Cell Linker Kit enables consistent and stable labeling of cell membrane lipid regions for cell tracing and proliferation studies in vitro and in vivo. It should be applied exclusively to membrane-specific applications, as it is not intended for intracellular or non-membrane labeling. Appropriate use ensures high specificity, low toxicity, and reliable results in cell biology research.
-
RCN2 Drives ESCC Metastasis and Cisplatin Resistance via PI3
2026-06-19
This study reveals RCN2 as a central driver of metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC) by promoting PPP2CA degradation through UBR5, leading to sustained PI3K-AKT pathway activation. These findings highlight a novel molecular axis underlying therapy failure in ESCC and suggest actionable targets for overcoming resistance.
-
MAPK10-Mediated KRT16 Phosphorylation Suppresses NSCLC Metas
2026-06-19
This study uncovers how MAPK10 phosphorylates keratin 16 (KRT16), promoting its ubiquitination and subsequent degradation, which limits non-small cell lung cancer (NSCLC) metastasis. The research establishes the MAPK10/KRT16/RNF213 axis as a mechanistically defined prognostic biomarker and therapeutic target, offering new insights for intervention strategies.
-
2-Deoxy-D-glucose: Decoding Glycolysis Control in Osteogenes
2026-06-18
Explore how 2-Deoxy-D-glucose (2-DG) uniquely illuminates glycolytic regulation in bone formation and cancer research. This in-depth guide links new scientific findings to practical assay design, setting it apart from prior applications.
-
Baicalin: Advanced Mechanistic Insights for Adult Neuroplast
2026-06-18
Explore how Baicalin modulates the KEAP1-NRF2/HO-1 pathway to restore adult neuroplasticity and enhance cancer research. This in-depth analysis uncovers unique mechanistic findings and practical assay considerations not addressed in typical workflows.
-
BAPTA-AM: Precision Cell-Permeable Calcium Chelator for Assa
2026-06-17
BAPTA-AM stands out as a cell-permeable calcium chelator, enabling precise control of intracellular Ca²⁺ for apoptosis, neuroprotection, and real-time calcium imaging workflows. Recent evidence highlights its unique value in dissecting mitochondrial dysfunction-driven neurodegeneration, empowering researchers to design robust, reproducible assays.
-
Nutrient Restriction and Retinoic Acid Drive Meiotic Entry i
2026-06-17
This study introduces a robust in vitro system where retinoic acid (RA) and nutrient restriction synergistically induce meiotic initiation in long-term cultured mouse spermatogonial stem cells (SSCs). The work addresses a persistent challenge in reproductive biology, expanding potential for mechanistic meiosis research and translational applications.
-
Dabigatran etexilate: Direct Thrombin Inhibitor for Research
2026-06-16
Dabigatran etexilate is a potent oral direct thrombin inhibitor with well-characterized anticoagulant effects and high selectivity. Its clinical utility in stroke prevention for atrial fibrillation is established, with mechanistic clarity and robust benchmarks. APExBIO supplies Dabigatran etexilate (A8381) for advanced research applications.
-
Roscovitine (Seliciclib): Protocols and Workflow Mastery
2026-06-16
Roscovitine (Seliciclib, CYC202) empowers researchers with precise, reversible cell cycle arrest and proven tumor growth inhibition, making it a keystone tool for dissecting cyclin-dependent kinase signaling in cancer biology. This guide translates advanced bench protocols, troubleshooting, and workflow innovations into actionable strategies, uniquely leveraging APExBIO’s high-quality formulation.
-
Vorinostat (SAHA, MK0683): Reliable HDAC Inhibition in Cance
2026-06-15
Optimize cell viability and apoptosis assays with Vorinostat (SAHA, MK0683), SKU A4084. This evidence-based guide addresses common laboratory questions, protocol challenges, and product selection, ensuring reproducible results for cancer biology and epigenetic modulation workflows.
-
Microbiota–Tryptophan–AhR Axis in Ulcerative Colitis Repair
2026-06-15
Li et al. reveal that Huangqin decoction (HQD) repairs ulcerative colitis by reshaping gut microbiota, boosting microbial tryptophan metabolites, and activating the aryl hydrocarbon receptor (AhR) to drive intestinal stem cell differentiation. This elucidates a novel microbiota–tryptophan–AhR–ISC axis central to mucosal healing, with implications for targeted interventions in inflammatory bowel disease.